Terpos Evangelos, Politou Marianna, Ntanasis-Stathopoulos Ioannis, Karalis Vangelis, Merkouri Efrosyni, Fotiou Despina, Gavriatopoulou Maria, Malandrakis Panagiotis, Kastritis Efstathios, Trougakos Ioannis P, Dimopoulos Meletios A
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, PS 11528 Athens, Greece.
Hematology Laboratory-Blood Bank, Aretaieio Hospital, School of Medicine, National and Kapodistrian University of Athens, PS 11528 Athens, Greece.
Vaccines (Basel). 2021 Jul 1;9(7):712. doi: 10.3390/vaccines9070712.
It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis. The aim of this prospective study was to evaluate the presence of antibodies against heparin/PF4 in adults who received a first dose of the ChAdOx1 nCov-19 vaccine, and correlate them with clinical data and antibody responses to the vaccine. We detected non-platelet activating anti-PF4 antibodies in 67% (29/43) of the vaccinated individuals on day 22 following the first dose of the ChAdOx1 nCov-19 vaccine, though these were detected in low titers. Furthermore, there was no correlation between the presence of anti-PF4 IgG antibodies and the baseline clinical characteristics of the patients. Our findings suggest that the ChAdOx1 nCov-19 vaccine can elicit anti-PF4 antibody production even in recipients without a clinical manifestation of thrombosis. The presence of anti-PF4 antibodies was not sufficient to provoke clinically evident thrombosis. Our results offer an important insight into the ongoing investigations regarding the underlying multifactorial pathophysiology of thrombotic events induced by the ChAdOx1 nCov-19 vaccine.
对于未发生血栓形成的接种ChAdOx1 nCov - 19疫苗的个体，该疫苗是否能诱导抗PF4抗体的产生尚不清楚。这项前瞻性研究的目的是评估接种第一剂ChAdOx1 nCov - 19疫苗的成年人中抗肝素/PF4抗体的存在情况，并将其与临床数据以及对疫苗的抗体反应相关联。在接种第一剂ChAdOx1 nCov - 19疫苗后的第22天，我们在67%（29/43）的接种个体中检测到了非血小板活化抗PF4抗体，不过这些抗体的滴度较低。此外，抗PF4 IgG抗体的存在与患者的基线临床特征之间没有相关性。我们的研究结果表明，即使在没有血栓形成临床表现的受种者中，ChAdOx1 nCov - 19疫苗也能引发抗PF4抗体的产生。抗PF4抗体的存在不足以引发临床上明显的血栓形成。我们的结果为正在进行的关于ChAdOx1 nCov - 19疫苗诱导的血栓形成事件潜在多因素病理生理学的研究提供了重要见解。
